Technology Bundle ID
NCI-E-202-2020

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Applications
Therapeutics
Lead Inventors
Barry O’Keefe (NCI)
Brice Wilson (NCI)
Christina Schroeder (NCI)
Christopher Marchand (NCI)
Johan Rosengren (University, Australia)
Lauren Krumpe (Leidos Biomedical)
Yyes Pommier (NCI)
Development Status
Discovery (Lead Identification)
ICs
NCI

Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors such as camptothecin, rinotecan, and topotecan are widely used anti-cancer agents that work by stabilizing the TOP1-DNA cleavage complex. Stabilization causes irreversible double-strand DNA breaks, eventually leading to the death of replicating cancer cells. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that plays a role in allowing cells to escape from TOP1 inhibitor-induced cell death by catalyzing the clearance of TOP1-DNA complexes. This activity led researchers to consider TDP1 a molecular target for the sensitization of replicating cancer cells to camptothecin and related chemotherapeutic agents.

Scientists at the National Cancer Institute (NCI) discovered recifin, a unique cysteine-rich cyclic peptide that inhibits the human protein tyrosyl-DNA phosphodiesterase 1 (TDP1). The peptide was isolated from a natural source, the sponge Axinella sp. The three-dimensional structure of recifin was determined by NMR and found to represent a completely new structural class unlike previously published cyclic peptides. Recifin inhibits TDP1 via an allosteric mechanism of inhibition and is the first identified allosteric inhibitor of this protein. TDP1 is important for cancer chemotherapy because its inhibition can restore cancer-cell sensitivity to clinically-used topoisomerase inhibitors.

NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents.

Commercial Applications
  • Treatment for various solid cancers previously chemoresistant to some degree – such as small cell lung and ovarian cancer 
  • Development of new chemosensitizing agents: inhibition of tyrosyl-DNA phosphodiesterase 1 (TDP1), an important DNA repair enzyme in humans and a promising inhibition target 

 

Competitive Advantages
  • Numerous commercialization and/or sub-licensing opportunities due to wide range of relevant cancers.
  • First-in-class drug; Recifin is the first member of a new family of cyclic peptides that inhibits the enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1)
  • First-in-class with effective and safe chemosensitizer to TOP1 inhibitors 
  • Potential for improved clinical responses
  • TDP1 inhibitors can sensitize cancer cells to chemotherapeutic agents – including topotecan and irinotecan
  • Recifin is stable to protease digestion
  • Scale-up manufacturing: recifin analogues could be created with simple, automated peptide synthesis 
  • Sensitizing cells to topoisomerase I (TOP1) inhibitors, including topotecan, irinotecan and related chemotherapeutic agents

 

Request More Info

Licensing Contact: